Symbols / ABSI Stock $5.30 -1.03% Absci Corporation

Healthcare • Biotechnology • United States • NMS
ABSI (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Sean McClain
Exch · Country NMS · United States
Market Cap 826.30M
Enterprise Value 705.01M
Income -118.44M
Sales 1.84M
FCF (ttm) -41.48M
Book/sh 1.11
Cash/sh 0.81
Employees 140
Insider 10d —
IPO Jul 22, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -7.94
PEG —
P/S 450.05
P/B 4.79
P/C —
EV/EBITDA -6.05
EV/Sales 383.99
Quick Ratio 6.28
Current Ratio 6.59
Debt/Eq 2.57
LT Debt/Eq —
EPS (ttm) -0.82
EPS next Y -0.67
EPS Growth —
Revenue Growth -81.80%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-05-07
ROA -37.33%
ROE -63.89%
ROIC —
Gross Margin 0.00%
Oper. Margin -143.47%
Profit Margin 0.00%
Shs Outstand 155.91M
Shs Float 146.14M
Insider Own 13.02%
Instit Own 69.31%
Short Float 26.89%
Short Ratio 7.26
Short Interest 33.71M
52W High 6.72
vs 52W High -21.13%
52W Low 2.24
vs 52W Low 136.61%
Beta 2.38
Impl. Vol. 12.50%
Rel Volume 0.76
Avg Volume 4.35M
Volume 3.32M
Target (mean) $8.53
Tgt Median $8.50
Tgt Low $4.20
Tgt High $12.00
# Analysts 8
Recom Strong_buy
Prev Close $5.36
Price $5.30
Change -1.03%
About

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$8.53
Mean price target
2. Current target
$5.30
Latest analyst target
3. DCF / Fair value
$-4.79
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.30
Low
$4.20
High
$12.00
Mean
$8.53

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-08 main Truist Securities Buy → Buy $11
2026-03-30 reit Needham Buy → Buy $7
2026-03-25 reit Needham Buy → Buy $7
2026-03-18 reit Needham Buy → Buy $7
2025-12-18 main HC Wainwright & Co. Buy → Buy $8
2025-12-12 reit Needham Buy → Buy $7
2025-11-13 main Needham Buy → Buy $7
2025-10-02 init JP Morgan — → Overweight —
2025-08-18 main Morgan Stanley Overweight → Overweight $6
2025-08-13 main Needham Buy → Buy $8
2025-07-28 main Morgan Stanley Overweight → Overweight $6
2025-05-14 reit Needham Buy → Buy $9
2025-04-16 main Keybanc Overweight → Overweight $9
2025-04-09 reit Needham Buy → Buy $9
2025-03-20 reit Guggenheim Buy → Buy $10
2025-03-19 reit Needham Buy → Buy $9
2025-03-19 reit HC Wainwright & Co. Buy → Buy $7
2025-01-22 init Needham — → Buy $9
2025-01-17 reit HC Wainwright & Co. Buy → Buy $7
2025-01-10 reit HC Wainwright & Co. Buy → Buy $7
News
RSS: Latest ABSI news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-12 BUSCH ANDREAS Officer — 100,000 $2.29 $229,000
2026-03-02 MCCLAIN SEAN Chief Executive Officer — 406,200 $0.00 $0
2026-03-02 MCCLAIN SEAN Chief Executive Officer — 406,200 $0.00 $0
2026-03-02 BEDRICK TODD Officer — 49,600 $0.00 $0
2026-03-02 BEDRICK TODD Officer — 49,600 $0.00 $0
2026-03-02 JONASSON ZACHARIAH Chief Financial Officer — 135,400 $0.00 $0
2026-03-02 JONASSON ZACHARIAH Chairman of the Board — 135,400 $0.00 $0
2026-03-02 WALKER SHELBY J Officer — 90,300 $0.00 $0
2026-03-02 WALKER SHELBY J Officer — 90,300 $0.00 $0
2026-03-02 PANGALOS MENELAS N Director — 5,800 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
2.80
-38.24%
4.53
-20.71%
5.72
-0.50%
5.75
Operating Revenue
2.80
-38.24%
4.53
-20.71%
5.72
-0.50%
5.75
Operating Expense
128.22
+13.05%
113.42
+13.54%
99.90
-11.20%
112.50
Research And Development
81.42
+27.50%
63.86
+32.85%
48.07
-18.40%
58.91
Selling General And Administration
35.06
-3.09%
36.17
-4.38%
37.83
-6.71%
40.55
Total Expenses
128.22
+13.05%
113.42
+13.54%
99.90
-11.20%
112.50
Operating Income
-125.42
-15.18%
-108.89
-15.62%
-94.18
+11.78%
-106.75
Total Operating Income As Reported
-120.32
-10.50%
-108.89
+5.74%
-115.52
-8.21%
-106.75
EBITDA
-103.16
-15.81%
-89.08
+6.68%
-95.46
-4.56%
-91.29
Normalized EBITDA
-108.26
-21.53%
-89.08
-20.18%
-74.12
+18.81%
-91.29
Reconciled Depreciation
11.74
-12.30%
13.39
-4.36%
14.00
+6.86%
13.10
EBIT
-114.91
-12.13%
-102.47
+6.38%
-109.46
-4.85%
-104.39
Total Unusual Items
5.10
0.00
+100.00%
-21.34
0.00
Total Unusual Items Excluding Goodwill
5.10
0.00
+100.00%
-21.34
0.00
Special Income Charges
5.10
0.00
+100.00%
-21.34
0.00
Impairment Of Capital Assets
—
0.00
-100.00%
21.34
0.00
Restructuring And Mergern Acquisition
-5.10
0.00
—
—
Net Income
-115.18
-11.71%
-103.11
+6.75%
-110.57
-5.40%
-104.90
Pretax Income
-115.11
-11.72%
-103.04
+6.73%
-110.47
-4.84%
-105.36
Net Non Operating Interest Income Expense
-0.21
+63.01%
-0.56
+44.06%
-1.01
-3.91%
-0.97
Interest Expense Non Operating
0.21
-63.01%
0.56
-44.06%
1.01
+3.91%
0.97
Net Interest Income
-0.21
+63.01%
-0.56
+44.06%
-1.01
-3.91%
-0.97
Interest Expense
0.21
-63.01%
0.56
-44.06%
1.01
+3.91%
0.97
Other Income Expense
10.51
+63.83%
6.42
+142.01%
-15.28
-748.11%
2.36
Other Non Operating Income Expenses
5.41
-15.66%
6.42
+5.91%
6.06
+157.06%
2.36
Tax Provision
0.07
-1.43%
0.07
-30.00%
0.10
+121.69%
-0.46
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+5150.00%
0.00
Tax Effect Of Unusual Items
1.07
0.00
+100.00%
-4.48
0.00
Net Income Including Noncontrolling Interests
-115.18
-11.71%
-103.11
+6.75%
-110.57
-5.40%
-104.90
Net Income From Continuing Operation Net Minority Interest
-115.18
-11.71%
-103.11
+6.75%
-110.57
-5.40%
-104.90
Net Income From Continuing And Discontinued Operation
-115.18
-11.71%
-103.11
+6.75%
-110.57
-5.40%
-104.90
Net Income Continuous Operations
-115.18
-11.71%
-103.11
+6.75%
-110.57
-5.40%
-104.90
Normalized Income
-119.21
-15.62%
-103.11
-10.03%
-93.71
+10.67%
-104.90
Net Income Common Stockholders
-115.18
-11.71%
-103.11
+6.75%
-110.57
-5.40%
-104.90
Otherunder Preferred Stock Dividend
—
—
—
—
Diluted EPS
-0.84
+10.64%
-0.94
+21.67%
-1.20
-4.35%
-1.15
Basic EPS
-0.84
+10.64%
-0.94
+21.67%
-1.20
-4.35%
-1.15
Basic Average Shares
136.78
+24.07%
110.24
+19.79%
92.03
+1.30%
90.85
Diluted Average Shares
136.78
+24.07%
110.24
+19.79%
92.03
+1.30%
90.85
Diluted NI Availto Com Stockholders
-115.18
-11.71%
-103.11
+6.75%
-110.57
-5.40%
-104.90
Depreciation Amortization Depletion Income Statement
11.74
-12.30%
13.39
-4.36%
14.00
+7.38%
13.04
Depreciation And Amortization In Income Statement
11.74
-12.30%
13.39
-4.36%
14.00
+7.38%
13.04
Preferred Stock Dividends
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
216.30
+1.26%
213.61
-1.70%
217.30
-32.31%
321.01
Current Assets
149.57
+11.76%
133.83
+10.99%
120.58
-35.47%
186.86
Cash Cash Equivalents And Short Term Investments
144.29
+28.35%
112.42
+15.12%
97.66
-40.61%
164.43
Cash And Cash Equivalents
20.02
-51.41%
41.21
-43.05%
72.36
+20.69%
59.95
Other Short Term Investments
124.27
+74.50%
71.21
+181.50%
25.30
-75.79%
104.48
Receivables
—
0.00
-100.00%
2.19
+41.23%
1.55
Accounts Receivable
—
0.00
-100.00%
2.19
—
Other Receivables
—
—
2.19
+41.23%
1.55
Prepaid Assets
—
—
—
—
Restricted Cash
0.00
-100.00%
15.95
-1.52%
16.19
+7.79%
15.02
Other Current Assets
5.28
-3.26%
5.46
+20.32%
4.54
-22.56%
5.86
Total Non Current Assets
66.72
-16.36%
79.78
-17.52%
96.72
-27.90%
134.15
Net PPE
23.77
-28.25%
33.13
-27.68%
45.82
-21.06%
58.04
Gross PPE
59.29
-8.36%
64.70
-7.31%
69.81
-4.69%
73.25
Accumulated Depreciation
-35.52
-12.51%
-31.57
-31.59%
-23.99
-57.80%
-15.20
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
3.74
-41.49%
6.38
+3.45%
6.17
-6.56%
6.61
Construction In Progress
—
—
0.00
-100.00%
0.29
Other Properties
28.48
-8.91%
31.26
-14.56%
36.59
-7.34%
39.49
Leases
27.08
+0.08%
27.06
+0.03%
27.05
+0.70%
26.86
Goodwill And Other Intangible Assets
41.51
-7.51%
44.88
-6.98%
48.25
-33.86%
72.96
Goodwill
—
—
0.00
-100.00%
21.34
Other Intangible Assets
41.51
-7.51%
44.88
-6.98%
48.25
-6.53%
51.62
Other Non Current Assets
1.44
-18.36%
1.76
-33.60%
2.65
-15.80%
3.15
Total Liabilities Net Minority Interest
26.85
-22.12%
34.48
-16.16%
41.12
-11.74%
46.59
Current Liabilities
22.77
-20.56%
28.66
-3.05%
29.56
-2.35%
30.27
Payables And Accrued Expenses
19.35
+85.17%
10.45
+29.70%
8.06
-64.81%
22.89
Payables
2.76
-6.51%
2.95
+96.14%
1.50
-37.69%
2.41
Accounts Payable
2.76
-6.51%
2.95
+96.14%
1.50
-37.69%
2.41
Current Accrued Expenses
16.59
+121.20%
7.50
+14.47%
6.55
-68.00%
20.48
Current Debt And Capital Lease Obligation
2.68
-38.31%
4.34
-22.18%
5.58
-19.53%
6.93
Current Debt
0.87
-68.06%
2.73
-16.11%
3.26
+10.59%
2.95
Other Current Borrowings
0.87
-68.06%
2.73
-16.11%
3.26
+10.59%
2.95
Current Capital Lease Obligation
1.80
+12.25%
1.61
-30.69%
2.32
-41.80%
3.99
Current Deferred Liabilities
0.74
-33.78%
1.12
-64.84%
3.17
+613.26%
0.45
Current Deferred Revenue
0.74
-33.78%
1.12
-64.84%
3.17
+613.26%
0.45
Other Current Liabilities
—
12.75
+0.00%
12.75
—
Total Non Current Liabilities Net Minority Interest
4.08
-29.83%
5.82
-49.68%
11.56
-29.16%
16.32
Long Term Debt And Capital Lease Obligation
2.62
-53.85%
5.69
-44.81%
10.30
-35.81%
16.05
Long Term Debt
—
1.26
-73.03%
4.66
-41.63%
7.98
Long Term Capital Lease Obligation
2.62
-40.75%
4.43
-21.51%
5.64
-30.05%
8.07
Non Current Deferred Liabilities
0.44
0.00
-100.00%
0.97
+305.88%
0.24
Non Current Deferred Revenue
0.44
0.00
-100.00%
0.97
0.00
Non Current Deferred Taxes Liabilities
—
—
0.19
-21.85%
0.24
Other Non Current Liabilities
1.02
+669.17%
0.13
-54.92%
0.29
+742.86%
0.04
Stockholders Equity
189.45
+5.76%
179.13
+1.68%
176.18
-35.80%
274.41
Common Stock Equity
189.45
+5.76%
179.13
+1.68%
176.18
-35.80%
274.41
Capital Stock
0.01
+25.00%
0.01
+33.33%
0.01
+0.00%
0.01
Common Stock
0.01
+25.00%
0.01
+33.33%
0.01
+0.00%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
151.52
+31.34%
115.36
+23.93%
93.09
+0.73%
92.41
Ordinary Shares Number
151.52
+31.34%
115.36
+23.93%
93.09
+0.73%
92.41
Additional Paid In Capital
813.63
+18.14%
688.73
+18.20%
582.70
+2.15%
570.45
Retained Earnings
-624.78
-22.60%
-509.60
-25.36%
-406.50
-37.36%
-295.93
Gains Losses Not Affecting Retained Earnings
0.59
+14875.00%
-0.00
+89.19%
-0.04
+69.17%
-0.12
Other Equity Adjustments
0.59
+14875.00%
-0.00
+89.19%
-0.04
+69.17%
-0.12
Total Equity Gross Minority Interest
189.45
+5.76%
179.13
+1.68%
176.18
-35.80%
274.41
Total Capitalization
189.45
+5.02%
180.39
-0.25%
180.84
-35.96%
282.40
Working Capital
126.81
+20.57%
105.17
+15.55%
91.02
-41.87%
156.59
Invested Capital
190.32
+3.93%
183.12
-0.53%
184.09
-35.48%
285.34
Total Debt
5.30
-47.12%
10.03
-36.86%
15.88
-30.90%
22.98
Capital Lease Obligations
4.43
-26.64%
6.04
-24.19%
7.96
-33.93%
12.05
Net Tangible Assets
147.94
+10.19%
134.25
+4.95%
127.92
-36.50%
201.46
Tangible Book Value
147.94
+10.19%
134.25
+4.95%
127.92
-36.50%
201.46
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-92.92
-28.35%
-72.40
-12.01%
-64.64
+20.54%
-81.34
Cash Flow From Continuing Operating Activities
-92.92
-28.35%
-72.40
-12.01%
-64.64
+20.47%
-81.28
Net Income From Continuing Operations
-115.18
-11.71%
-103.11
+6.75%
-110.57
-5.40%
-104.90
Depreciation Amortization Depletion
11.74
-12.30%
13.39
-4.36%
14.00
+6.86%
13.10
Depreciation
—
—
10.60
+9.28%
9.70
Amortization Cash Flow
—
—
3.40
+0.00%
3.40
Depreciation And Amortization
11.74
-12.30%
13.39
-4.36%
14.00
+6.86%
13.10
Amortization Of Intangibles
—
—
3.40
+0.00%
3.40
Other Non Cash Items
-5.68
-387.99%
1.97
+491.02%
0.33
-49.24%
0.66
Stock Based Compensation
18.32
-5.81%
19.45
+70.39%
11.42
-8.96%
12.54
Asset Impairment Charge
—
0.00
-100.00%
21.34
0.00
Deferred Tax
—
—
-0.05
+89.70%
-0.51
Deferred Income Tax
—
—
-0.05
+89.70%
-0.51
Operating Gains Losses
—
—
—
—
Gain Loss On Investment Securities
—
—
—
—
Net Foreign Currency Exchange Gain Loss
—
—
—
—
Change In Working Capital
0.42
+214.95%
-0.37
-124.26%
1.52
+198.51%
-1.54
Change In Receivables
0.00
-100.00%
2.24
+436.19%
-0.67
-350.00%
-0.15
Changes In Account Receivables
0.00
-100.00%
2.24
+436.19%
-0.67
—
Change In Prepaid Assets
-0.42
+12.40%
-0.48
-130.29%
1.60
-32.91%
2.38
Change In Payables And Accrued Expense
1.09
-36.80%
1.73
+186.59%
-2.00
+10.76%
-2.24
Change In Accrued Expense
—
-0.29
+75.68%
-1.21
+28.94%
-1.71
Change In Payable
—
2.03
+357.76%
-0.79
-47.47%
-0.53
Change In Account Payable
—
2.03
+357.76%
-0.79
-47.47%
-0.53
Change In Other Working Capital
-0.50
+86.90%
-3.79
-233.36%
2.84
+283.52%
-1.55
Change In Other Current Assets
0.25
+466.18%
-0.07
+73.33%
-0.26
-2061.54%
0.01
Investing Cash Flow
-50.16
-20.64%
-41.58
-150.74%
81.94
+164.53%
-126.98
Cash Flow From Continuing Investing Activities
-50.16
-20.64%
-41.58
-150.74%
81.94
+164.53%
-126.98
Net PPE Purchase And Sale
0.20
-61.68%
0.54
+188.28%
-0.61
+96.22%
-16.04
Purchase Of PPE
-1.11
-174.01%
-0.40
+53.02%
-0.86
+94.68%
-16.18
Sale Of PPE
1.31
+39.72%
0.94
+269.69%
0.25
+90.98%
0.13
Capital Expenditure
-1.11
-174.01%
-0.40
+53.02%
-0.86
+94.68%
-16.18
Net Investment Purchase And Sale
-50.37
-19.60%
-42.11
-151.01%
82.55
+179.69%
-103.59
Purchase Of Investment
-119.87
+35.59%
-186.11
-26.31%
-147.35
-35.69%
-108.59
Sale Of Investment
69.50
-51.74%
144.00
-37.36%
229.90
+4497.94%
5.00
Net Business Purchase And Sale
—
—
0.00
+100.00%
-8.00
Purchase Of Business
—
—
0.00
+100.00%
-8.00
Net Other Investing Changes
—
—
—
0.65
Financing Cash Flow
105.95
+28.38%
82.53
+1940.87%
-4.48
-185.60%
5.24
Cash Flow From Continuing Financing Activities
105.95
+28.38%
82.53
+1940.87%
-4.48
-185.60%
5.24
Net Issuance Payments Of Debt
-3.20
+20.71%
-4.03
+24.58%
-5.34
-216.68%
4.58
Issuance Of Debt
—
—
0.00
-100.00%
12.03
Repayment Of Debt
-3.20
+20.71%
-4.03
+24.58%
-5.34
+28.26%
-7.45
Long Term Debt Issuance
—
—
0.00
-100.00%
12.03
Long Term Debt Payments
-3.20
+20.71%
-4.03
+24.58%
-5.34
+28.26%
-7.45
Net Long Term Debt Issuance
-3.20
+20.71%
-4.03
+24.58%
-5.34
-216.68%
4.58
Net Common Stock Issuance
105.83
+28.44%
82.40
+9458.93%
0.86
+31.40%
0.66
Proceeds From Stock Option Exercised
3.31
-20.41%
4.16
—
—
Changes In Cash
-37.14
-18.07%
-31.45
-345.25%
12.82
+106.32%
-203.08
Beginning Cash Position
58.21
-35.08%
89.67
+16.69%
76.84
-72.55%
279.93
End Cash Position
21.08
-63.79%
58.21
-35.08%
89.67
+16.69%
76.84
Free Cash Flow
-94.03
-29.15%
-72.81
-11.16%
-65.50
+32.83%
-97.51
Interest Paid Supplemental Data
0.18
-68.27%
0.56
-42.16%
0.97
+8.38%
0.90
Amortization Of Securities
-2.54
+32.06%
-3.74
-40.13%
-2.67
-288.23%
-0.69
Common Stock Issuance
105.83
+28.44%
82.40
+9458.93%
0.86
+31.40%
0.66
Issuance Of Capital Stock
105.83
+28.44%
82.40
+9458.93%
0.86
+31.40%
0.66
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category